Caraco Pharmaceutical (CPD) Granted Tentative FDA Approval for Generic Zyrtec
More News related to CPD
- Caraco Pharma Ltd. (CPD) Posts Q3 Loss of $0.08, Wider than Estimates
- Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010
- Caraco Pharmaceutical Labs (CPD) Posts Q3 EPS of $0.17
- Morning Movers 9/30: HOKU, ICCC, VSR, CFW, DSCO Higher; CIT, HX, RGN, ICON, APAB, RMTI Lower
- Caraco Pharmaceutical (CRD) In Consent Decree with FDA Providing Path to Resume Manufacturing Operations
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) said the FDA has granted tentative approval for the Company's Abbreviated New Drug Application for Cetirizine Hydrochloride Chewable Tablets, 5 mg and 10 mg. Final approval to market this product is anticipated subsequent to the expiry of patent protection on December 25, 2007.
Related Categories
FDAStocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
